Clinical Trial Update: Bendamustine, Cytarabine, Etoposide and Melphalan (BeEAM) as Conditioning for Autologous Stem Cell Transplant (ASCT) in Aggressive Non Hodgkin's Lymphoma (NHL). [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BeEAM conditioning (bendamustine, cytarabine, etoposide, melphalan) for autologous stem cell transplant in patients with aggressive non…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aggressive Non-hodgkin Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• CYTARABINE (CYTARABINE)
• Etoposide (Etoposide)
• Melphalan (Melphalan)

Snippet

Sponsor: Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea | Conditions: Bendamustine, Conditioning Therapy | Phase 2 | Status: COMPLETED